Parexel Chairman Josef von Rickenbach on Shifting CRO Models In Asia For Efficient Drug Development: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Roughly two-thirds of contract research organization Parexel's $1.1 billion 2010 revenue base was outside of the U.S., including about 12 percent in the Asia/Pacific region, and Chairman and CEO Josef von Rickenbach expects its share of APAC business to increase. In Tokyo for a day-long Parexel seminar to draw new clients in Japan, von Rickenbach and VP-Asia/Pacific Albert Liou spoke with PharmAsia News' Tokyo bureau about the company's shifting client base in Asia and the evolving partnership model in the CRO market in part one of this interview..
You may also be interested in...
Japan's Improved Clinical Trial Requirements Bring Positive Impact To China, Korea Development
The new openness provides opportunities for drug makers because it is no longer necessary to delegate all work to a Japanese partner, but the message is slow getting out.
Japan's Improved Clinical Trial Requirements Bring Positive Impact To China, Korea Development
The new openness provides opportunities for drug makers because it is no longer necessary to delegate all work to a Japanese partner, but the message is slow getting out.
Japan's Improved Clinical Trial Requirements Bring Positive Impact To China, Korea Development
TOKYO - Japan's drug regulator Pharmaceuticals and Medical Devices Agency has opened its doors in the last three years to preapproval discussions with drug companies. While the move has helped somewhat to ease the agency's drug approval lag, it can also pay benefits to companies applying for approvals in neighboring Asian countries